US Stock Insider Trading | Vir Biotechnology Discloses 5 Insider Transactions on February 24

K-LinePoet · 2026-03-07T04:28:27+00:00

Vir Biotechnology disclosed multiple insider transactions on February 24, 2026, including stock sales by director De Backer Marianne and executives, highlighting the trading activity of the company's leadership. The company is committed to innovative therapies to boost the immune system, focusing on the research and development of serious infectious diseases and cancer.

K-LinePoet

2026-03-07 04:28:27

Abstract generation in progress

On February 24, 2026, Vir Biotechnology (VIR) disclosed five insider transactions. Director Marianne De Backer sold 19,000 shares on February 23, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Executive	O’Byrne Jason	February 23, 2026	Sell	2,089	7.45	15,600
February 24, 2026	Director	De Backer Marianne	February 23, 2026	Sell	19,000	7.45	141,900
February 24, 2026	Executive	Eisner Mark	February 23, 2026	Sell	2,089	7.45	15,600
February 24, 2026	Executive	de Verneuil Vanina	February 23, 2026	Sell	4,445	7.45	33,100
February 24, 2026	Executive	Sabatini Brent	February 23, 2026	Sell	1,829	7.45	13,600
February 18, 2026	Executive	Sabatini Brent	February 13, 2026	Sell	1,530	7.79	11,900
February 3, 2026	Director	Vicki L. Sato	February 2, 2026	Sell	22,000	7.71	169,700
December 3, 2025	Shareholder holding over 10%	SVF Endurance (Cayman) Ltd	December 1, 2025	Sell	191,900	5.98	1,147,800
December 1, 2025	Shareholder holding over 10%	SVF Endurance (Cayman) Ltd	November 28, 2025	Sell	61,500	6.44	396,000
December 1, 2025	Shareholder holding over 10%	SVF Endurance (Cayman) Ltd	November 26, 2025	Sell	127,900	6.39	817,700

【Company Profile】

Vir Biotechnology, Inc. was incorporated on April 7, 2016, under the laws of Delaware. As a clinical-stage biopharmaceutical company, VIR is dedicated to enhancing the immune system to develop innovative therapies for serious infectious diseases and cancer. The company’s approach focuses on addressing complex mechanisms that allow these threats to evade immune defenses. Vir’s clinical pipeline includes therapies targeting delta hepatitis virus and various solid tumors, with ongoing clinical projects and trials showing promising prospects for new standards of care. The company leverages its proprietary platforms DAISY and PRO-XTEN to optimize antibody development. With an experienced leadership team in immunology, infectious diseases, and oncology, VIR is committed to transforming lives through its groundbreaking therapies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.